Czernin J - Search Results

1

LUNAR: a randomized Phase 2 study of ¹⁷⁷ Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).

Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. Ma TM, et al. Among authors: czernin j. BJU Int. 2023 Jul;132(1):65-74. doi: 10.1111/bju.15988. Epub 2023 Mar 2. BJU Int. 2023. PMID: 36797449

2

Fibroblast Activation Protein Expression in Sarcomas.

Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Crane JN, et al. Among authors: czernin j. Sarcoma. 2023 Jun 9;2023:2480493. doi: 10.1155/2023/2480493. eCollection 2023. Sarcoma. 2023. PMID: 37333052 Free PMC article.

3

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.

Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Weber M, et al. Among authors: czernin j. Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.01.019. Online ahead of print. Eur Urol. 2024. PMID: 38490855 Free article.

4

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.

Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Nikitas J, et al. Among authors: czernin j. Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.01.021. Online ahead of print. Eur Urol. 2024. PMID: 38494380

5

Application of next-generation imaging in biochemically recurrent prostate cancer.

Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Moul JW, et al. Among authors: czernin j. Prostate Cancer Prostatic Dis. 2023 Sep 7. doi: 10.1038/s41391-023-00711-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37679601 Review.

6

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.

Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Shore ND, et al. Among authors: czernin j. Prostate Cancer Prostatic Dis. 2023 Sep 7. doi: 10.1038/s41391-023-00712-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37679602 Review.

7

Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.

Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Dumont RA, et al. Cancer Res. 2009 Apr 1;69(7):3173-9. doi: 10.1158/0008-5472.CAN-08-3390. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318569 Free PMC article.

8

Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.

Ganz PA, Czernin J. Ganz PA, et al. Among authors: czernin j. J Nucl Med. 2023 Oct;64(10):1506-1508. doi: 10.2967/jnumed.123.266602. J Nucl Med. 2023. PMID: 37788851 No abstract available.

9

From Physician to Leader in Global Research and Development: A Conversation Between Ken Song, Lisa Bodei, and Johannes Czernin.

Song K, Bodei L, Czernin J. Song K, et al. Among authors: czernin j. J Nucl Med. 2023 Jan;64(1):8-11. doi: 10.2967/jnumed.122.265135. J Nucl Med. 2023. PMID: 36599476 Free article. No abstract available.

10

Correction: Application of next-generation imaging in biochemically recurrent prostate cancer.

Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Moul JW, et al. Among authors: czernin j. Prostate Cancer Prostatic Dis. 2024 Jan 17. doi: 10.1038/s41391-024-00791-6. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38233472 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page